KR100668024B1 - 유방암, 난소암, 자궁내막암, 골수종 및 수막종 치료용 약제를 제조하기 위한 11베타-(4-아세틸페닐)-17베타-히드록시-17알파-(1,1,2,2,2-펜타플루오로에틸)에스트라-4,9-디엔-3-온의 용도 - Google Patents

유방암, 난소암, 자궁내막암, 골수종 및 수막종 치료용 약제를 제조하기 위한 11베타-(4-아세틸페닐)-17베타-히드록시-17알파-(1,1,2,2,2-펜타플루오로에틸)에스트라-4,9-디엔-3-온의 용도 Download PDF

Info

Publication number
KR100668024B1
KR100668024B1 KR1020037005360A KR20037005360A KR100668024B1 KR 100668024 B1 KR100668024 B1 KR 100668024B1 KR 1020037005360 A KR1020037005360 A KR 1020037005360A KR 20037005360 A KR20037005360 A KR 20037005360A KR 100668024 B1 KR100668024 B1 KR 100668024B1
Authority
KR
South Korea
Prior art keywords
antiprogestin
cancer
breast cancer
treatment
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020037005360A
Other languages
English (en)
Korean (ko)
Other versions
KR20030057540A (ko
Inventor
옌스 호프만
로제마리 리흐트너
게르하르트 지마이스터
마르틴 슈나이더
울리케 푸르만
Original Assignee
쉐링 악티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 쉐링 악티엔게젤샤프트 filed Critical 쉐링 악티엔게젤샤프트
Publication of KR20030057540A publication Critical patent/KR20030057540A/ko
Application granted granted Critical
Publication of KR100668024B1 publication Critical patent/KR100668024B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020037005360A 2000-10-18 2001-10-17 유방암, 난소암, 자궁내막암, 골수종 및 수막종 치료용 약제를 제조하기 위한 11베타-(4-아세틸페닐)-17베타-히드록시-17알파-(1,1,2,2,2-펜타플루오로에틸)에스트라-4,9-디엔-3-온의 용도 Expired - Fee Related KR100668024B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US24099100P 2000-10-18 2000-10-18
EP00250342 2000-10-18
US60/240,991 2000-10-18
EP00250342.3 2000-10-18
PCT/EP2001/012006 WO2002032432A1 (en) 2000-10-18 2001-10-17 Use of antiprogestins for the induction of apoptosis in a cell

Publications (2)

Publication Number Publication Date
KR20030057540A KR20030057540A (ko) 2003-07-04
KR100668024B1 true KR100668024B1 (ko) 2007-01-15

Family

ID=26072952

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020037005360A Expired - Fee Related KR100668024B1 (ko) 2000-10-18 2001-10-17 유방암, 난소암, 자궁내막암, 골수종 및 수막종 치료용 약제를 제조하기 위한 11베타-(4-아세틸페닐)-17베타-히드록시-17알파-(1,1,2,2,2-펜타플루오로에틸)에스트라-4,9-디엔-3-온의 용도

Country Status (28)

Country Link
EP (1) EP1326617B9 (https=)
JP (1) JP2004511523A (https=)
KR (1) KR100668024B1 (https=)
CN (1) CN1209111C (https=)
AT (1) ATE334683T1 (https=)
AU (2) AU2002223619B2 (https=)
BG (1) BG107744A (https=)
BR (1) BR0114696A (https=)
CA (1) CA2423020C (https=)
CY (1) CY1105745T1 (https=)
CZ (1) CZ299823B6 (https=)
DE (1) DE60121980T2 (https=)
DK (1) DK1326617T3 (https=)
EA (1) EA010593B1 (https=)
EE (1) EE200300157A (https=)
ES (1) ES2269492T3 (https=)
HR (1) HRP20030388A2 (https=)
HU (1) HUP0301433A3 (https=)
IL (2) IL154976A0 (https=)
MX (1) MXPA03002955A (https=)
NO (1) NO20031741L (https=)
NZ (1) NZ538347A (https=)
PL (1) PL360157A1 (https=)
PT (1) PT1326617E (https=)
SI (1) SI1326617T1 (https=)
SK (1) SK4702003A3 (https=)
UA (1) UA76729C2 (https=)
WO (1) WO2002032432A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY27301A1 (es) * 2001-05-25 2003-02-28 Schering Ag Uso y composiciones de antiprogestinas para el tratamiento de enfermedades de la próstata
US20040242551A1 (en) * 2003-05-28 2004-12-02 Schering Ag Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases
WO2008128786A1 (en) * 2007-04-23 2008-10-30 Bayer Schering Pharma Aktiengesellschaft Combination of progesterone-receptor antagonist together with a lutein-hormone-releasing hormone agonist and antagonist for use in brca mediated diseases
EP2136796A2 (en) * 2007-04-23 2009-12-30 Bayer Schering Pharma Aktiengesellschaft Progesterone-receptor antagonist for use in brca-mediated cancer alone or as combination with antiestrogen
US20080268041A1 (en) * 2007-04-23 2008-10-30 Jens Hoffmann Combination of progesterone-receptor antagonist together with none-steroidal antiestrogen for use in brca mediated diseases
GB0718167D0 (en) 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target
JP6092880B2 (ja) * 2011-10-04 2017-03-08 インヴァイヴィス ファーマスーティカルズ インコーポレーテッドＩｎｖｉｖｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 抗プロゲスチン感受性腫瘍を特定および治療する方法ならびに系

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19706061A1 (de) * 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette

Also Published As

Publication number Publication date
EP1326617B9 (en) 2006-10-25
HRP20030388A2 (en) 2005-04-30
ES2269492T3 (es) 2007-04-01
EA010593B1 (ru) 2008-10-30
IL154976A0 (en) 2003-10-31
DK1326617T3 (da) 2006-12-18
CZ299823B6 (cs) 2008-12-03
EE200300157A (et) 2003-08-15
DE60121980D1 (de) 2006-09-14
HK1062273A1 (en) 2004-10-29
MXPA03002955A (es) 2003-08-07
DE60121980T2 (de) 2007-03-01
IL154976A (en) 2007-05-15
EA200300479A1 (ru) 2003-10-30
EP1326617A1 (en) 2003-07-16
CA2423020A1 (en) 2002-04-25
HUP0301433A2 (hu) 2003-10-28
ATE334683T1 (de) 2006-08-15
CA2423020C (en) 2009-01-20
BG107744A (bg) 2004-02-27
CN1209111C (zh) 2005-07-06
UA76729C2 (uk) 2006-09-15
NO20031741L (no) 2003-06-17
CY1105745T1 (el) 2010-12-22
WO2002032432A1 (en) 2002-04-25
PL360157A1 (en) 2004-09-06
EP1326617B1 (en) 2006-08-02
NZ538347A (en) 2007-03-30
SI1326617T1 (sl) 2007-02-28
PT1326617E (pt) 2006-12-29
BR0114696A (pt) 2003-11-18
SK4702003A3 (en) 2004-01-08
AU2002223619B2 (en) 2006-08-24
AU2361902A (en) 2002-04-29
HUP0301433A3 (en) 2010-01-28
KR20030057540A (ko) 2003-07-04
NO20031741D0 (no) 2003-04-15
CN1469749A (zh) 2004-01-21
JP2004511523A (ja) 2004-04-15

Similar Documents

Publication Publication Date Title
KR100632908B1 (ko) 호르몬-의존성 질병의 예방 및 치료를 위한항프로게스틴의 용도
KR100668024B1 (ko) 유방암, 난소암, 자궁내막암, 골수종 및 수막종 치료용 약제를 제조하기 위한 11베타-(4-아세틸페닐)-17베타-히드록시-17알파-(1,1,2,2,2-펜타플루오로에틸)에스트라-4,9-디엔-3-온의 용도
AU2002223619A1 (en) Use of antiprogestins for the induction of apoptosis in a cell
US20040072811A1 (en) Use of antiprogestins for the induction of apoptosis in a cell
KR20060005412A (ko) 호르몬-의존성 질환의 예방 및 치료를 위한 항프로게스틴및 순수한 항에스트로겐을 포함하는 조성물
US20040053898A1 (en) Combination preparation with a erbeta selective estrogen and serm or antiestorgen
TWI306403B (en) Use of antiprogestings for the induction of apoptosis in a cell
TWI312680B (en) Use of antiprogesting for prophylaxis and treatment of hormone-dependent diseases
HK1062273B (en) Use of antiprogestins for the induction of apoptosis in a cell
RS50389B (sr) Upotreba antiprogestina za profilaksu i lečenje hormonskih zavisnih bolesti

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20100106

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20100106

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000